Actively Recruiting
Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
Led by Women's Hospital School Of Medicine Zhejiang University · Updated on 2025-12-01
39
Participants Needed
1
Research Sites
326 weeks
Total Duration
On this page
Sponsors
W
Women's Hospital School Of Medicine Zhejiang University
Lead Sponsor
X
Xiangya Hospital of Central South University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Exploring the therapeutic effect of neoadjuvant chemotherapy combined with PD-1 inhibitor camrelizumab on advanced stage III-IV endometrial cancer
CONDITIONS
Official Title
Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with stage III non-operable resectable or stage IV endometrial cancer by imaging evaluation
- Pathologically confirmed endometrioid endometrial cancer
- Female patients aged between 18 and 75 years
- ECOG performance status score of 0 or 1
- Able to tolerate surgery and radiotherapy
- Laboratory tests with WBC ≥ 3.5 x10^9/L, neutrophils ≥ 1.5 x10^9/L, platelets ≥ 80 x10^9/L, and organ function parameters within acceptable limits
- Able to comply with follow-up and study requirements
- Able to provide informed consent and comply with the study protocol
You will not qualify if you...
- Active or history of autoimmune disease except certain stable conditions like vitiligo, alopecia areata, Graves' disease, psoriasis, eczema, asymptomatic hypothyroidism, type 1 diabetes with stable insulin, or childhood asthma without adult symptoms
- Prior treatment with immune checkpoint inhibitors such as anti-PD-1, anti-PD-L1, or CTLA-4 antibodies
- Known allergy to any component of the study treatments
- Use of immunosuppressive drugs or systemic corticosteroids (>10 mg/day prednisone or equivalent) within 2 weeks before trial dosing
- Use of herbs or drugs with immunomodulatory effects within 2 weeks before trial
- Active systemic infections or serious infections within 4 weeks before dosing
- Untreated chronic hepatitis B or active hepatitis C
- Active tuberculosis or suspected active tuberculosis
- Immunodeficiency or HIV positive
- Active inflammatory bowel disease or history of such disease
- Known symptomatic interstitial lung disease
- Live or attenuated vaccine within 4 weeks prior to dosing (except inactivated flu vaccine)
- Prior bone marrow or solid organ transplant
- History of primary malignant tumors within 5 years
- Major surgery or severe trauma within 28 days prior to dosing
- History of gastrointestinal or female genital fistula
- Uncontrolled cardiovascular diseases, bleeding disorders, or other significant co-morbidities
- Pregnant or breastfeeding women or women of childbearing potential not using contraception
- Participation in other interventional clinical trials
- Any condition that may increase risk or interfere with study evaluation as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Women's hospital school of medicine zhejiang university
Hangzhou, Zhejiang, China, 310000
Actively Recruiting
Research Team
Y
Yang Li, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here